GENERAL INFORMATION
Established:  2000
Type:  Graduated from Technological Incubator
Ownership:  Private
Parent:  Ofakim Innovative Technologies

Core business

Diagnostic and novel drug target discovery of complex atopic
polygenic diseases.

Employees:  6
Main Markets:  Biotech and Pharmaceutical Companies.

Overview

Established in January 2000, Linkagene Ltd. is a start up company
conducting research on atopic complex polygenic diseases.
LinkaGene has developed unique research strategy and
bio-informatics tools, which combine accurate clinical
definitions with state of the art molecular biology, genetics and
statistics.
LinkaGene intends to establish itself as a leading player in the
development of fast and accurate diagnostic tools and discovery
of novel drug targets for complex atopic diseases such as asthma,
allergy, cardiovascular disease, diabetes, CNS diseases and
alcoholism.

LinkaGene specializes in the combined use of homogeneous founder
population, DNA microarrays and genetic mapping studies to reveal
the association of gene de-regulation and genetic variations with
complex diseases.
Homogeneous genetic populations advantages include less
background noise, fewer genes causing the disease, and a
relatively low number of mutations as compared to outbred
populations. The combination of the use of founder populations as
biological source, with high throughput, state of the art
molecular biology tools and statistical analysis allows for the
fast development of accurate diagnostic tools and discovery of
novel drug targets.

LinkaGene platforms offer to both biotech and pharmaceutical
companies significant advantages to boost their drug development
and clinical capabilities.

LinkaGene recognizes the need to allow for diversification of the
company risks. LinkaGene therefore, seeks partnership and
strategic alliances with biotech and pharmaceutical companies at
several levels of the development chain to allow for revenues in
the form of R&D funding, milestone payments and royalties of
future sales.